Table 1 Sample demographics.

From: Genetic influences on antidepressant side effects: a CYP2C19 gene variation and polygenic risk study in the Estonian Biobank

Characteristic

Subcategory

Cases (%)

Controls (%)

Total (%)

Sex

Female

5932 (83.1%)

5084 (71.2%)

11016 (80.2%)

 

Male

1209 (16.9%)

1504 (21.1%)

2713 (19.8%)

Age

Mean Age (years ± SD)

47.4 ± 13.9

54.7 ± 13.8

49.9 ± 14.3

Metaboliser

Poor Metaboliser

108 (2.2%)

73 (1.5%)

181 (1.9%)

phenotype

Intermediate Metaboliser

1221 (24.7%)

1137 (23.0%)

2358 (24.7%)

 

Normal Metaboliser

1806 (36.5%)

1690 (34.1%)

3496 (36.6%)

 

Rapid Metaboliser

1528 (30.9%)

1379 (27.9%)

2907 (30.4%)

 

Ultrarapid Metaboliser

288 (5.8%)

333 (6.7%)

621 (6.5%)

Subgroup

Depression

5923 (43.1%)

4991 (32.7%)

10914 (79.5%)

  1. Percentages for cases and controls are calculated within each subcategory based on the total number of cases or controls for the characteristic. Total percentages are based on the entire study population (N = 13,729), except for metaboliser phenotype where the percentages are calculated only for participants who took drugs metabolised by CYP2C19 (N = 9563), including escitalopram, citalopram, sertraline, and amitriptyline and had complete CNV and star allele information. Cases were defined as individuals reporting a specific side effect for a drug or drug class, while controls were antidepressant users that did not report that specific side effect.
Back to article page